07:00 , Oct 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MEK

Neurology INDICATION: Anxiety Zebrafish studies suggest MEK inhibitors could help treat anxiety caused by overactive cAMP signaling. In zebrafish larvae, a phosphodiesterase-4 (PDE-4) inhibitor promoted cAMP signaling and induced anxiety-like behaviors. Screening of 80 kinase inhibitor tool...
08:00 , Feb 7, 2011 |  BioCentury  |  Product Development

Keep It Simple

Genaissance Pharmaceuticals Inc. thought it would leverage its pharmacogenomics expertise in 2004 when it acquired Viibryd vilazodone, a compound that had failed five Phase II trials for depression. But the problem with Viibryd turned out...
07:00 , Oct 14, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Rett syndrome Serotonin (5-HT1A) receptor; solute carrier family 6 neurotransmitter transporter GABA member...
07:00 , Oct 7, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Pain; neurology Serotonin (5-HT1A) receptor A study in mice identified pyridylmethylamine-based...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

BCI-952: Phase II data

A modified intent-to-treat (mITT) analysis of 134 patients in a double-blind, U.S. Phase II trial showed that BCI-952 met the co-primary endpoint of significantly improving mean CGI-I score at week 6 compared with placebo (p=0.046),...
00:07 , Jul 28, 2009 |  BC Extra  |  Clinical News

BrainCells reports BCI-952 data

BrainCells Inc. (San Diego, Calif.) reported mixed results from a Phase II trial of BCI-952 to treat major depressive disorder (MDD). A modified intent-to-treat (ITT) analysis showed the combination of low-dose buspirone and melatonin met...
07:00 , Jun 19, 2006 |  BioCentury  |  Product Development

More is less in CNS

Running clinical trials can be complicated when some of the disease symptoms a compound is designed to treat are also side effects of the compound. MediciNova Inc. ran into just such a conundrum with its...
08:00 , Mar 27, 2006 |  BC Week In Review  |  Clinical News

Celexa citalopram: Phase IV data

Data from the Phase IV STAR*D study in 1,439 evaluable patients, with nonpsychotic major depressive disorder who had no remission of symptoms with citalopram treatment or could not tolerate citalopram, showed that both alternate treatments...
08:00 , Mar 10, 2003 |  BC Week In Review  |  Clinical News

Buspirone: Phase III

BVF discontinued development of its once-daily buspirone after data from a Phase III trial showed that the compound failed to significantly change HAM-A scores compared to placebo, the primary endpoint. Bristol-Myers Squibb Co. (BMY,...
08:00 , Mar 10, 2003 |  BC Extra  |  Financial News

BMY shifting R&D spend, reports earnings

Bristol-Myers (BMY) said on a conference call Monday that it will not grow its R&D budget this year and it will shift a significant portion of its R&D spend to later-stage from discovery programs. A...